Navigation Links
GlySure CEO to Present ICU Trial Results at Spring Medtech Industry Conferences
Date:3/26/2013

OXFORD, England, March 26, 2013 /PRNewswire/ --

GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, will present the results of its cardiac surgery intensive care trial and plans for CE mark testing at two leading MedTech conferences this spring. GlySure CEO Christopher Jones will speak at the inaugural Biovision Investor Conference on March 26th, 2013 in Lyon, France, and at the Investment In Innovation (IN³) Medical Device 360° Conference on April 17th, 2013 in Dublin, Ireland.

Studies have shown that inadequate post-operative blood sugar control in heart surgery patients is associated with an increased risk of major complications and death. GlySure recently completed a trial of its CBGM system on cardiac surgery patients.  The study revealed GlySure's technology can be used to continuously measure glucose levels with an extremely high degree of accuracy and repeatability across two-to-five days of a patient's stay in ICU, which is key to effectively implementing TGC.

At the Biovision Investor Conference and IN³ Medical Device 360° Conference, Jones will share results of GlySure's cardiac surgery ICU trial and outline the company's plans for CE regulatory trials, which are set to commence this Spring.

Biovision has selected GlySure as one of 35 life science companies to present to its forum of international capital investors and large healthcare companies seeking partnerships and innovation, while the producers of the (IN³) Medical Device 360° Conference have chosen GlySure as one of 35 early stage companies to appear before its global audience of VCs, top investors and corporate acquirers.

About GlySure:

GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU).  The company has demonstrated through ICU testing highly accurate sensors, which can provide continuous glucose readings throughout the length of a patient's stay in the ICU.  GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 20 employees. The company's products are not approved for use in the U.S. or Europe. http://www.glysure.com

Media Contact: Kara Della Vecchia , KDV Communications, Inc. Tel: +1-508-314-3127. kara@kdvcommunications.com


'/>"/>
SOURCE GlySure
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GlySure Earns ISO 13485 Certification
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
4. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
5. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
6. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
8. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
9. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
10. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
11. Anlit to Present New Dietary Supplements for Children at Vitafoods Europe 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research ... Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, Growth ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 ... Mn by 2024, expanding at a CAGR of 5.6% from ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the ... Cardiology Devices segment is likely to create absolute $ opportunity ... over 2017. By the end of 2027, Cardiology Devices segment ... 700 Mn, expanding at a CAGR of 18.4% over the ... Asia Pacific reprocessed medical devices market in terms ...
(Date:4/19/2017)... NASHVILLE , Tenn. and DALLAS , ... and EndoStim, Inc., announced that the first patients in ... with the EndoStim device in the Lower Esophageal Sphincter ... is a minimally-invasive implantable device designed to provide long-term ... through neurostimulation. GERD affects nearly 65 million ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a ... solutions, today announced that Kyle Allain has joined the company as Vice President ... and operations, including provider, payor and managed care solutions. , A seasoned ...
(Date:4/24/2017)... ... April 24, 2017 , ... In 2017, ... diagnosed globally; approximately 25,000 of them will be malignant.(1) As research into precision ... type of healthcare model in the diagnosis and treatment of brain tumors. Healthcare ...
(Date:4/24/2017)... ... April 24, 2017 , ... Rod Burkett, CEO of Gardant Management ... , Rod has been at the forefront of Gardant since it was founded in ... has overseen the opening of more than 40 new senior living communities. With his ...
(Date:4/24/2017)... ... April 24, 2017 , ... As a former supermodel known for her timeless ... news for single women is that she put all the words in her new ... Joan's insight, personal experiences and sparkling sense of humor have inspired her to write ...
(Date:4/24/2017)... ... April 24, 2017 , ... Labs ... makes it difficult for lab operators and management to assess these processes with ... identify wasteful or unnecessary actions. , Created with the help of both ...
Breaking Medicine News(10 mins):